INS and metabolic dysfunction-associated steatohepatitis: Although previous studies have suggested that NASH patients treated with TZDs experience improvement in steatosis, lobular inflammation, and hepatocellular ballooning, findings regarding the effects of TZD treatment on hepatic fibrosis have been inconsistent.[23,29,31] Various TZD regimens have also been shown to improve insulin sensitivity in NASH patients,[14,20–22] but the effects of TZDs on important hyperglycemia and adiposity-related variables have not comprehensively assessed across RCTs.